New drug combo for blood cancer tested in early trial

NCT ID NCT05590377

Terminated Disease control Sponsor: Teva Branded Pharmaceutical Products R&D LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a new drug called modakafusp alfa combined with daratumumab in 15 people with multiple myeloma that had returned or not responded to prior treatments. The main goals were to check safety and find the best dose. The trial was terminated early, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: modakafusp alfa and daratumumab
What this could lead to: If it works, this combination could offer a new treatment option for people with multiple myeloma that has come back or stopped responding to other therapies.
What could go wrong: This was a very early, small trial (only 15 participants) that was terminated, so results are limited. The combination may cause side effects and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Banner MD Anderson Cancer Center

Gilbert, Arizona, 85234, United States
CHRU Lille

Lille, Hauts-de-France, 59037, France
Cedars-Sinai Medical Center

Los Angeles, California, 77598, United States
Centre Hospitalier Universitaire De Sherbrooke (CHUS) - Centre de Recherche Clinique Etienne-Le Bel (CRCELB) Hopital Fleurimont

Sherbrooke, Quebec, J1H 5N4, Canada
Chonnam National University Hwasun Hospital

Hwasun, Jeollanam-do, 58128, South Korea
Concord Repatriation General Hospital

Concord, New South Wales, 2139, Australia
Floating Hospital for Children at Tufts Medical Center

Boston, Massachusetts, 02111, United States
Fort Wayne Medical Oncology and Hematology, Inc

Fort Wayne, Indiana, 46060, United States
Fundacion Instituto de Estudios Ciencias de la Salud de Castilla y Leon-Investigacion Biomedica de Salamanca (IBSAL)

Salamanca, 37007, Spain
HCA Midwest Health (Midwest Ventures Group HCA MidAmerica Division)

Overland Park, Kansas, 66211, United States
Hospital Universitario Vall d'Hebron

Barcelona, 08035, Spain
Institut Paoli-Calmettes

Marseille, Provence-Alpes-Côte d'Azur Region, 13273, France
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

Tianjin, Tianjin Municipality, 300020, China
New York Cancer and Blood Specialists

Bay Shore, New York, 11706, United States
Samsung Medical Center

Seoul, 06351, South Korea
Stony Brook University Hospital

Stony Brook, New York, 11794, United States
Summit Medical Group PA

Florham Park, New Jersey, 07932, United States
Sun Yat-Sen University Cancer Center

Guangzhou, Guangdong, 510060, China
The Alfred Hospital

Melbourne, Victoria, 3004, Australia
The Catholic University of Korea, Seoul St. Marys Hospital

Seoul, 06591, South Korea
Tranquil Clinical Research

Webster, Texas, 78041, United States
Tulane University Health Sciences Center

New Orleans, Louisiana, 70112, United States
University of Cincinnati - Vontz Center for Molecular Studies

Cincinnati, Ohio, 45267, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States
Washington University School of Medicine

St Louis, Missouri, 63130, United States
Wuhan Union Hospital

Wuhan, Hubei, 430022, China
Zhejiang University School of Medicine - The First Affiliated Hospital (Zhejiang Provincial First Hospital)

Hangzhou, Zhejiang, 310003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.